Navigation Links
MannKind to Present at Upcoming Conferences
Date:6/16/2008

VALENCIA, Calif., June 16 /PRNewswire-FirstCall/ -- MannKind Corporation (Nasdaq: MNKD), focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at upcoming conferences.

-- 18th Annual Wachovia Nantucket Equity Conference on Monday, June 23,

2008 at 11:45 AM (Eastern Time) at The White Elephant in Nantucket

Island, Massachusetts

-- 2nd Annual Jefferies Healthcare Conference on Thursday, June 26, 2008

at 2:00 PM (Eastern Time) in New York

Interested parties can access a link to the live web cast of the presentations in the Investor Relations section of the Company's website at http://www.mannkindcorp.com. A replay of each presentation will be available for 14 days.

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. Its lead product, the Technosphere(R) Insulin System, is currently in phase 3 clinical trials in the United States, Europe and Latin America to study its safety and efficacy in the treatment of diabetes. For more information on MannKind Corporation and its technology, visit http://www.mannkindcorp.com.


'/>"/>
SOURCE MannKind Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. MannKind to Present at the UBS Global Life Sciences Conference
2. MannKind Corporation Raises $250 Million in Self Managed Registered Direct Offerings of Common Stock
3. MannKind Announces Positive Results from a Phase 1a Study of a GLP-1 Formulation
4. MannKind to Present at the Piper Jaffray Healthcare Conference
5. MannKind to Present at the Wachovia 2008 Healthcare Conference
6. MannKind to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
7. MannKind Corporation to Hold Fourth Quarter Financial Results Conference Call on March 4, 2008
8. MannKind Corporation Response to Recent Market Events
9. Matthew J. Pfeffer Joins MannKind as Corporate Vice President and Chief Financial Officer
10. MannKind Corporation to Hold First Quarter Financial Results Conference Call on May 5, 2008
11. MannKind to Present at the Morgan Stanley Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2017)... ... July 26, 2017 , ... NLP ... the years of diagnostic excellence by Mayo Clinic and the experience in developing ... will be distributed through the Microsoft Azure platform and will focus on assisting ...
(Date:7/26/2017)... , July 26, 2017  Nurse practitioners play a ... the findings of a Merck Manuals survey released ... medical conference, revealed that most (88 percent) believe they spend ... treatments and prescriptions. ... Merck Manuals survey of 210 nurse ...
(Date:7/25/2017)... ... July 25, 2017 , ... ... and improve efficiency of livestock farming while reducing the use of antibiotics and ... intellectual property from Cornell University. , These new proprietary technologies expand the ...
(Date:7/24/2017)... ... July 24, 2017 , ... ... US and Canada who have proven their superior service quality as rated by ... Staffing as an industry leader based on service quality ratings from their placed ...
Breaking Biology Technology:
(Date:4/11/2017)... 2017 Research and Markets has announced the ... to their offering. ... eye tracking market to grow at a CAGR of 30.37% during ... Market 2017-2021, has been prepared based on an in-depth market analysis ... and its growth prospects over the coming years. The report also ...
(Date:4/5/2017)... April 5, 2017  The Allen Institute for Cell ... Explorer: a one-of-a-kind portal and dynamic digital window into ... data, the first application of deep learning to create ... cell lines and a growing suite of powerful tools. ... these and future publicly available resources created and shared ...
(Date:4/3/2017)... , April 3, 2017  Data ... precision engineering platform, detected a statistically significant ... product prior to treatment and objective response ... the potential to predict whether cancer patients ... to treatment, as well as to improve ...
Breaking Biology News(10 mins):